S

AN FRANCISCO — Celgene (CELG) did not buy Bluebird Bio (BLUE). Instead, it said Sunday that it was purchasing a private company developing a me-too myelofibrosis drug with safety issues that, if approved, will need to fight for patients with an entrenched and well-regarded competitor.

It’s only a slight exaggeration to say investors gathered here were expecting to stream into the J.P. Morgan Healthcare conference Monday morning giddy with news of blockbuster biotech M&A. Celgene’s acquisition of Impact Biomedicines for $1.1 billion up front — and up to $7 billion total if all regulatory and sales milestones are are met — is not that deal.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy